Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD)

Abstract MUC1 is a glycoprotein expressed on the luminal surface of simple epithelia. In carcinoma, MUC1 overexpression is associated with malignancy. In breast cancer patients, increased levels of circulating MUC1 (CA 15.3 tumor marker) are associated with poor prognosis (Tumour Biol.2005; 26:217–20). In myeloma, MUC1 overexpression correlates with apoptosis resistance. We have previously shown (Br J Haematol.2003; 120:344–52) that MUC1 is selectively found in differentiating erythroid cells suggesting a possible role as cross-talk molecule between erythroblasts and bone marrow microenvironment during erythropoiesis. In CD34+ cells cultured in the presence of EPO and SCF, MUC1 is expressed before Glycophorin A (GlyA) during the erythroid differentiation process, and disappears following GlyA up-regulation. Aiming to evaluate the role of MUC1 in the erythroid counterpart present in neoplastic haemopoiesis, we studied MUC1 serum circulating levels in patients affected by Ph-negative Myeloproliferative Chronic Disorders (MPD). We analysed serum samples from 42 MPD patients affected by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) (N 25, 14, and 3, respectively). CA15.3 (soluble MUC1) levels were determined using the commercially available ADVIA Centaur CA 15.3 assay (Bayer Corporation, NY) and cut off level was set at 25 U/mL. As control group serum samples from healthy donors, matched for sex and age, were also analyzed. Evaluation of the humoral immune response to MUC1 protein core was performed in ELISA. Results indicated that CA15.3 levels were statistically higher in MPD patients than in the control group (p<0.005), this difference was more evident in PV patients (p<0.001) and in female cases (p<0.001). The JAK2V617F mutation status was not associated with CA15.3 values; similarly, neither the clinical or hematological features nor the clinical complications (thrombosis) were influenced byCA15.3 levels. Analysis of the humoral immune response to MUC1 core protein showed no substantial changes in serum anti-MUC1 IgG titers in PV patients, suggesting that in PV increase of soluble MUC1 does not induce immune responses against this self-antigen. Further studies are ongoing to investigate the significance of MUC1 in the development and onset of myeloproliferative disorders. In conclusion, MUC1 levels seem to be increased in PV patients, suggesting that further evaluations on large series of cases should include this test in the diagnostic work-up to PV patients.

Download Full-text

Evaluation of Passive Immunity Induced by Immunisation Using Two Inactivated gE-deleted Marker Vaccines against Infectious Bovine Rhinotracheitis (IBR) in Calves

Vaccines ◽

10.3390/vaccines8010014 ◽

2020 ◽

Vol 8 (1) ◽

pp. 14

Author(s):

Stefano Petrini ◽

Cecilia Righi ◽

Carmen Iscaro ◽

Giulio Viola ◽

Paola Gobbi ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Calf Serum ◽

Passive Immunity ◽

Control Group ◽

Infectious Bovine Rhinotracheitis ◽

Serum Samples ◽

Glycoprotein E ◽

Humoral Immune ◽

Newborn Calves

Different types of vaccines against Infectious Bovine Rhinotracheitis (IBR) are commercially available. Among these, inactivated glycoprotein E (gE)-deleted marker vaccines are commonly used, but their ability to induce passive immunity is poorly known. Here, we evaluated the passive immunity transferred from dams immunised with commercial inactivated gE-deleted marker vaccines to calves. We vaccinated 12 pregnant cattle devoid of neutralising antibodies against Bovine alphaherpesvirus 1 (BoHV-1) and divided them into two groups with 6 animals each. Both groups were injected with a different inactivated gE-deleted marker vaccine administrated via intranasal or intramuscular routes. An additional 6 pregnant cattle served as the unvaccinated control group. After calving, the number of animals in each group was increased by the newborn calves. In the dams, the humoral immune response was evaluated before calving and, subsequently, at different times until post-calving day 180 (PCD180). In addition, the antibodies in colostrum, milk, and in serum samples from newborn calves were evaluated at different times until PCD180. The results indicated that inactivated glycoprotein E (gE)-deleted marker vaccines are safe and produce a good humoral immune response in pregnant cattle until calving and PCD180. Moreover, results showed that, in calf serum, passive immunity persists until PCD180.

Download Full-text

Humoral Immune Response against Tumoral Mucin 1 (MUC1) in Breast Cancer Patients

The International Journal of Biological Markers ◽

10.5301/jbm.5000036 ◽

2013 ◽

Vol 28 (3) ◽

pp. 318-325 ◽

Cited By ~ 6

Author(s):

Marina T. Isla Larrain ◽

Andrea G. Colussi ◽

Sandra O. Demichelis ◽

Alberto Barbera ◽

Aldo Cretón ◽

...

Keyword(s):

Breast Cancer ◽

Immune Response ◽

Humoral Immune Response ◽

Benign Disease ◽

Breast Cancer Patients ◽

Mucin 1 ◽

Mcf7 Cells ◽

Serum Samples ◽

Humoral Immune ◽

Cancer Tissues

The aim of this study was to elucidate whether the IgG humoral immune response to breast cancer cells is directed to the aberrant mucin-1 (MUC1) associated to this type of cancer. To this aim, an adaptation of immunohistochemistry (IHC) was performed on samples of 45 breast cancer tissues, 12 benign disease tissues, and 31 normal tissues, incubated with matched serum samples from the same patients. Each serum sample was also incubated, with a modified immunocytochemistry (ICC), with MCF7 cells. In both techniques, serum was employed instead of the primary antibody. In the case of IHC, the reactivity with sera diminished when added after previous incubation of the tumor/tissue with an anti-MUC1 mAb; the reduction in reactivity was: from 93% to 44% in breast cancer tissues, and from 100% to 67% in benign disease tissues. The reactivity of normal samples (36%) remained unchanged. In the case of ICC, the reactivity with sera decreased after incubation with anti-MUC1 mAb from 71% to 16% in breast cancer tissues, from 83% to 0% in benign disease tissues, and from 52% to 10% in normal serum samples. These results were confirmed employing siRNA MUC1 transient gene knockdown. By Western blot analysis – after immunoprecipitation (IP) of the circulating MUC1– and ELISA, the TF antigen was detected in circulating MUC1 in all breast cancer and benign samples while Tn was detected in 38% of the samples. The existence of IgG autoantibodies against aberrantly glycosylated MUC1 may have a protective role and may contribute to a better prognosis in some patients. Enhancement of this natural immune response may constitute an alternative therapeutic strategy.

Download Full-text

Impact of Prebiotics and Synbiotics Administered in ovo on the Immune Response against Experimental Antigens in Chicken Broilers

Animals ◽

10.3390/ani10040643 ◽

2020 ◽

Vol 10 (4) ◽

pp. 643

Author(s):

Tadeusz Stefaniak ◽

Jan P. Madej ◽

Stanisław Graczyk ◽

Maria Siwek ◽

Ewa Łukaszewicz ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Physiological Saline ◽

Treated Group ◽

Delayed Type Hypersensitivity ◽

Saline Control ◽

Control Group ◽

In Ovo ◽

Humoral Immune ◽

Air Chamber

The effect of the in ovo application of selected prebiotics and synbiotics on the humoral immune response against T-dependent (SRBC) and T-independent (dextran) antigens and delayed-type hypersensitivity (DTH) to phytohemagglutinin was studied. On the 12th day of incubation, 800 eggs (Ross 308) were divided into five groups and injected into the egg air chamber with prebiotic inulin (Pre1), Bi2tos (Pre2), a synbiotic composed of inulin and Lactococcus lactis subsp. lactis IBB SL1 (Syn1), a synbiotic composed of Bi2tos and L. lactis subsp. cremoris IBB SC1 (Syn2), and physiological saline (control group; C). The chickens were immunized twice at the 7th and 21st day of life with SRBC and dextran. A DTH test was performed on the 7th, 21st, and 35th day. The application of prebiotics and synbiotics had no significant effect on the humoral immune response. SRBC-immunized in ovo Pre1- and Pre2-treated chickens showed significantly higher serum IgG levels than the control. A significant effect on the DTH reaction was detected on the 7th (Pre1 < C) and 21st (Pre2 > Syn2) day. However; Bi2tos may transiently stimulate the cellular immune response on the 21st day. It may be concluded that the application of inulin in an egg air chamber on the 12th day of incubation may stimulate the secondary immune response. The inulin-treated group exhibited a lower mortality rate than the control group.

Download Full-text

The Humoral Immune Response to Various Domains of Protective Antigen of Bacillus anthracis in Cutaneous Anthrax Cases in India

Defence Science Journal ◽

10.14429/dsj.66.10805 ◽

2016 ◽

Vol 66 (6) ◽

pp. 645 ◽

Cited By ~ 3

Author(s):

Anshul Varshney ◽

Nidhi Puranik ◽

M. Kumar ◽

A.K. Goel

Keyword(s):

Immune Response ◽

Bacillus Anthracis ◽

Humoral Immune Response ◽

Vaccine Development ◽

Protective Antigen ◽

Lethal Factor ◽

Serum Samples ◽

Public Health Importance ◽

Humoral Immune ◽

Cutaneous Anthrax

Anthrax, caused by Bacillus anthracis is known to occur globally since antiquity. Besides being an important biothreat agent, it is an important public health importance pathogen also in countries like India. B. anthracis secretes three distinct toxins, namely protective antigen (PA), lethal factor (LF) and edema factor (EF). PA is the central moiety of the anthrax toxin complex and therefore has been a molecule of choice for vaccine development. PA has four different domains with different functions. In this study, the major domains of PA were cloned and expressed in bacterial system. The purified recombinant proteins were used to determine the humoral immune response by ELISA using 43 human cutaneous anthrax serum samples. The maximum immunoreactivity was observed with the whole PA protein followed by domain 2, 4 and 1. The study corroborated that in addition to full PA, individual domain 2 and 4 can also be good target for vaccine development as well as for serodiagnostic assays for cutaneous anthrax

Download Full-text

Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal - Experimental Translational and Clinical ◽

10.1177/2055217317742425 ◽

2017 ◽

Vol 3 (4) ◽

pp. 205521731774242 ◽

Cited By ~ 1

Author(s):

Giannina Arru ◽

Elia Sechi ◽

Sara Mariotto ◽

Alessia Farinazzo ◽

Chiara Mancinelli ◽

...

Keyword(s):

Multiple Sclerosis ◽

Immune Response ◽

Neuromyelitis Optica ◽

Humoral Immune Response ◽

Serum Levels ◽

Spectrum Disorder ◽

Antigenic Peptides ◽

Neuromyelitis Optica Spectrum Disorder ◽

Serum Samples ◽

Humoral Immune

Background A specific humoral immune response against HERV-W envelope surface (env-su) glycoprotein antigens has been reported in serum of patients with multiple sclerosis (MS). However, it has not been evaluated to date in patients with neuromyelitis optica spectrum disorder (NMOSD). Objective The objective of this paper is to investigate whether antibody (Ab) response against HERV-W env-su antigenic peptides differs between NMOSD and MS. Methods Serum samples were collected from 36 patients with NMOSD, 36 patients with MS and 36 healthy control individuals (HCs). An indirect ELISA was set up to detect specific Abs against HERV-W env-su peptides. Results Our data showed that two antigenic peptides, particularly HERV-Wenv93–108 and HERV-Wenv248–262, were statistically significantly present only in serum of MS compared to NMOSD and HCs. Thus, the specific humoral immune response against HERV-W env-su glycoprotein antigens found in MS is widely missing in NMOSD. Conclusion Increased circulating serum levels of these HERV-W Abs may be suitable as additional biomarkers to better differentiate MS from NMOSD.

Download Full-text

Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection in the population of an oncology hospital in Poland. Criteria for COVID-19 re-immunization are needed.

10.21203/rs.3.rs-858160/v4 ◽

2021 ◽

Author(s):

Piotr Kosiorek ◽

Dorota Kazberuk ◽

Anna Hryniewicz ◽

Robert Milewski ◽

Samuel Stróż ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Post Infection ◽

Half Life ◽

Humoral Response ◽

Control Group ◽

Igg Antibodies ◽

Hospital Laboratory ◽

Humoral Immune ◽

Chemiluminescent Immunoassay

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. Our study aimed to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post-SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson & Johnson, and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in hospital laboratory by chemiluminescent immunoassay - CLIA, MAGLUMI. Results: 1. We observed a rise of antibodies response in both convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated asymptomatic SARS CoV-2 convalescents from the control group. Based on our analysis, we suggest that it is essential to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection and equivalent to the effectiveness of humoral response in convalescents and vaccinated people. Considering the time-limited nature of the effects of post-infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for the next vaccination.

Download Full-text

Differences in systemic humoral immune response among Balb/c mice administered with probiotic, LPS Escherichia coli, and probiotic-LPS E. coli

Iranian Journal of Microbiology ◽

10.18502/ijm.v11i4.1466 ◽

2019 ◽

Author(s):

Kurniawan Taufiq Kadafi ◽

Satrio Wibowo

Keyword(s):

Escherichia Coli ◽

Immune Response ◽

Humoral Immune Response ◽

Control Group ◽

E Coli ◽

Humoral Immune ◽

Treatment Regimens ◽

Humoral Immune Responses ◽

Group 4 ◽

Group 2

Background and Objectives: The aim of this study was to compare the systemic humoral immune responses, including IgE, IgA, IgG and IgM levels in Balb/c mice administered a probiotic, LPS derived from Escherichia coli (E.coli), and probiot- ic-LPS derived from E. coli. Materials and Methods: Thirty-two male Balb/c mice, 10-12 weeks of age with body weight ranging from 30-40 g were randomly divided into four experimental groups (n=8). The treatment regimens were as follows: Group 1, mice did not receive LPS or probiotic (control group); Group 2, mice received only LPS on the first day; Group 3, mice received probi- otic for 7 days; Group 4, mice received LPS on the first day, and then continued, with probiotic for 7 days. The mice were observed for 8 days, and then, euthanized the next day (day 9). The serum was collected, and the levels of IgE, IgA, IgG and IgM were measured using ELISA. Results: The humoral immune response was higher in the presence of a probiotic compared to that in the control; IgE (9.02 ± 0.58 units/ml, p=0.000), IgA (3.26 ± 0.99 units/ml, p=0.316), IgG (7.29 ± 0.24 units/ml, p=0.000), and IgM (4.01 ± 2.98 units/ml, p=0.505). When administered with LPS E. coli along with probiotic, the humoral immune response was the highest; IgE (10.68 ± 1.63 units/ml, p=0.000), IgA (8.34 ± 1.47 units/ml, p=0.000), IgG (9.96 ± 0.98 units/ml, p=0.000), and IgM (4.31 ± 1.05 units/ml, p=0.319) compared to the control group. Conclusion: Probiotic-LPS derived from E. coli treatment induced a higher humoral immune response (highest IgE, IgA, IgG and IgM levels) compared to treatment with probiotic only.

Download Full-text

Humoral immune response of Salmonella typhimurium and Salmonella enteritidis sonicated antigens in rabbits

The Iraqi Journal of Veterinary Medicine ◽

10.30539/iraqijvm.v36i0e.385 ◽

2012 ◽

Vol 36 (0E) ◽

pp. 84-88

Author(s):

Ekram A. Al-Samarrae

Keyword(s):

Immune Response ◽

Salmonella Typhimurium ◽

Humoral Immune Response ◽

Salmonella Enteritidis ◽

Agglutination Test ◽

Control Group ◽

Whole Cell ◽

Humoral Immune ◽

The Third ◽

Infected Goat

Salmonella typhimurium and salmonella enteritidis were isolated from infected goat andprepared an antigens of whole cell sonicated antigen of S.typhimurium(WCS.Ag.S.typhimurium ),whole cell sonicated antigen of S.enteritidis (WCS.Ag.S.entertidis) and combination of whole cell sonicated antigen (Salmonella typhimurium andSalmonella enteritidis) (CWS.Ag) . Their efficacy was evaluated by using tube agglutinationtest and enzyme linked immune sorbent assay (ELISA). Twenty rabbits were randomlydivided into four groups; the 1st group was immunized by WCS. Ag - Salmonella enteritidis,2nd group immunized by (WCS Ags .typhimurium), 3rd group immunized by CWCS.Agcompound and 4th left as control group which injected by physiological buffer saline (pH7.2). The antibody titer was increased in after the day 12, first, second and third months ofimmunization by agglutination test. IgG concentration was done by ELISA at the same time;which were recorded a higher significant differences (p˂ 0.01) at the first month in the groupimmunized by CWS Ag (449.65 ±38.6 1ng/ml IgG and 952± 20.85 antibodies titer )compared with other immunized groups ( WCS – Ag – S. enteritidis andWCS.Ag.S.typhimurium ). Also, the IgG concentration and antibodies titer are still higher inthe second and the third months in the immunized group by CWCS.Ag. 218.90± 6.69ng/ml,528± 68.58 and 89.55± 2.63ng/ml, 280± 49.98 respectively with significant differences (p˂0.01) compared with the immunized groups (WCS.Ag.S. entertidis and WCS. Ag.S.typhimurium) and also, they are significant (p˂ 0.01) when compared with the control groupResearch

Download Full-text

Humoral Response to Microbial Biomarkers in Rheumatoid Arthritis Patients

Journal of Clinical Medicine ◽

10.3390/jcm10215153 ◽

2021 ◽

Vol 10 (21) ◽

pp. 5153

Author(s):

Seyedesomaye Jasemi ◽

Gian Luca Erre ◽

Maria Luisa Cadoni ◽

Marco Bo ◽

Leonardo A. Sechi

Keyword(s):

Rheumatoid Arthritis ◽

Immune Response ◽

Humoral Immune Response ◽

Humoral Response ◽

Human Endogenous Retrovirus ◽

Serum Samples ◽

Humoral Immune ◽

Bivariate Correlation ◽

Microbial Biomarkers ◽

Significant Difference

Background/Objective: Chronic humoral immune response against multiple microbial antigens may play a crucial role in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to assess the prevalence and magnitude of antibody response against various bacterial and viral immunogen peptides in the sera of RA patients compared with the general population. Methods: Polyclonal IgG antibodies (Abs) specific for peptides derived from Porphyromonas gingivalis (RgpA, Kpg), Aggregatibacter actinomycetemcomitans (LtxA1, LtxA2), Mycobacterium avium subsp. paratuberculosis (MAP4027), Epstein–Barr virus (EBNA1, EBVBOLF), and human endogenous retrovirus (HERV-W env-su) were detected by ELISA in serum samples from 148 consecutive RA patients and 148 sex and age-matched healthy controls (HCs). In addition, the presence of a relationship between the positivity and the titer of antibodies and RA descriptors was explored by bivariate correlation analysis. Results: RA patients exhibit a higher prevalence of humoral immune response against all tested peptides compared to HCs with a statically significant difference for MAP4027 (30.4% vs. 10.1%), BOLF (25.7% vs. 8.1%), RgpA (24.3% vs. 9.4%), HERV W-env (20.3% vs. 9.4%), and EBNA1 (18.9% vs. 9.4%) peptides. Fifty-three (35.8%) out of 148 RA serum and 93 (62.8%) out of 148 HCs were negative for all pathogen-derived peptides. There was a significant correlation between OD values obtained by ELISA test against all peptides (p < 0.0001). We also found an increased titer and prevalence of Abs against LtxA1 and LtxA2 in seropositive vs. seronegative RF (p = 0.019, p = 0.018). Conclusion: This study demonstrates a significantly increased humoral response against multiple pathogens in patients with RA and implies that they could be an important factor in the pathogenesis of the disease. Therefore, the role of each individual pathogen in RA needs to be further investigated.

Download Full-text

Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection in the population of an oncology hospital in Poland. Criteria for COVID-19 re-immunization are needed.

10.21203/rs.3.rs-858160/v3 ◽

2021 ◽

Author(s):

Piotr Kosiorek ◽

Dorota Kazberuk ◽

Anna Hryniewicz ◽

Robert Milewski ◽

Samuel Stróż ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Post Infection ◽

Half Life ◽

Humoral Response ◽

Control Group ◽

Igg Antibodies ◽

Humoral Immune ◽

Chemiluminescent Immunoassay ◽

Oncology Center

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.

Download Full-text